FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3156570849> ?p ?o ?g. }

• W3156570849 endingPage "979" @default.
• W3156570849 startingPage "971" @default.
• W3156570849 abstract "ObjectiveAlthough screening for peripheral arterial disease (PAD) seems obvious due to its two to three times increased mortality, high prevalence in the elderly, ease of detection, and relatively harmless prevention, the evidence is sparse.MethodsA Markov decision model was created to model the lifetime effectiveness and cost effectiveness of general population PAD screening and relevant intervention in 65 year old men. The model was informed by original estimates from the VIVA trial data except for ankle brachial systolic blood pressure index test accuracy, quality of life, and background mortality, which were adopted from the literature. A Markov model was designed for 65 year old men, who were distributed in the starting states of no/detected/undetected PAD. The main outcomes were life years, quality adjusted life years, and costs of healthcare.ResultsScreening for PAD reduced the rates of amputations and stroke by 10.9% and 2.4%, respectively, while it increased the rates of revascularisation, acute myocardial infarction, and major bleeding by 5.5%, 7.1%, and 4.3% respectively. The overall life expectancy was increased by 14 days per invited subject. The cost per life year/quality adjusted life year was estimated at €16 717/€20 673. On the addition of low dose rivaroxaban reduced the costs per life year gained by 40%. If the model ran for only five follow up years, screening reduced relative mortality by 1.71%, suggesting PAD screening accounts for one fourth of the reported overall 7% relative mortality risk reduction of combined abdominal aortic aneurysm, PAD, and hypertension screening.ConclusionScreening of men for PAD is likely to be both clinically effective and cost effective in a lifetime perspective. Although screening for peripheral arterial disease (PAD) seems obvious due to its two to three times increased mortality, high prevalence in the elderly, ease of detection, and relatively harmless prevention, the evidence is sparse. A Markov decision model was created to model the lifetime effectiveness and cost effectiveness of general population PAD screening and relevant intervention in 65 year old men. The model was informed by original estimates from the VIVA trial data except for ankle brachial systolic blood pressure index test accuracy, quality of life, and background mortality, which were adopted from the literature. A Markov model was designed for 65 year old men, who were distributed in the starting states of no/detected/undetected PAD. The main outcomes were life years, quality adjusted life years, and costs of healthcare. Screening for PAD reduced the rates of amputations and stroke by 10.9% and 2.4%, respectively, while it increased the rates of revascularisation, acute myocardial infarction, and major bleeding by 5.5%, 7.1%, and 4.3% respectively. The overall life expectancy was increased by 14 days per invited subject. The cost per life year/quality adjusted life year was estimated at €16 717/€20 673. On the addition of low dose rivaroxaban reduced the costs per life year gained by 40%. If the model ran for only five follow up years, screening reduced relative mortality by 1.71%, suggesting PAD screening accounts for one fourth of the reported overall 7% relative mortality risk reduction of combined abdominal aortic aneurysm, PAD, and hypertension screening. Screening of men for PAD is likely to be both clinically effective and cost effective in a lifetime perspective." @default.
• W3156570849 created "2021-04-26" @default.
• W3156570849 creator A5041382502 @default.
• W3156570849 creator A5087872806 @default.
• W3156570849 date "2021-06-01" @default.
• W3156570849 modified "2023-10-03" @default.
• W3156570849 title "Clinical Benefit, Harm, and Cost Effectiveness of Screening Men for Peripheral Artery Disease: A Markov Model Based on the VIVA Trial" @default.
• W3156570849 cites W1503915976 @default.
• W3156570849 cites W1908289777 @default.
• W3156570849 cites W1964311749 @default.
• W3156570849 cites W1971047434 @default.
• W3156570849 cites W2000001886 @default.
• W3156570849 cites W2019734515 @default.
• W3156570849 cites W2063756400 @default.
• W3156570849 cites W2065680290 @default.
• W3156570849 cites W2080076783 @default.
• W3156570849 cites W2087242360 @default.
• W3156570849 cites W2100601303 @default.
• W3156570849 cites W2102924526 @default.
• W3156570849 cites W2114123088 @default.
• W3156570849 cites W2164795717 @default.
• W3156570849 cites W2271596670 @default.
• W3156570849 cites W2475357281 @default.
• W3156570849 cites W2745813324 @default.
• W3156570849 cites W2747829703 @default.
• W3156570849 cites W2788594318 @default.
• W3156570849 cites W2801198774 @default.
• W3156570849 cites W3040203384 @default.
• W3156570849 cites W3049484804 @default.
• W3156570849 cites W311320695 @default.
• W3156570849 cites W4229536675 @default.
• W3156570849 cites W4239553742 @default.
• W3156570849 cites W424467158 @default.
• W3156570849 cites W4289886312 @default.
• W3156570849 doi "https://doi.org/10.1016/j.ejvs.2021.02.039" @default.
• W3156570849 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33846075" @default.
• W3156570849 hasPublicationYear "2021" @default.
• W3156570849 type Work @default.
• W3156570849 sameAs 3156570849 @default.
• W3156570849 citedByCount "9" @default.
• W3156570849 countsByYear W31565708492021 @default.
• W3156570849 countsByYear W31565708492022 @default.
• W3156570849 countsByYear W31565708492023 @default.
• W3156570849 crossrefType "journal-article" @default.
• W3156570849 hasAuthorship W3156570849A5041382502 @default.
• W3156570849 hasAuthorship W3156570849A5087872806 @default.
• W3156570849 hasBestOaLocation W31565708491 @default.
• W3156570849 hasConcept C112930515 @default.
• W3156570849 hasConcept C126322002 @default.
• W3156570849 hasConcept C127413603 @default.
• W3156570849 hasConcept C133925201 @default.
• W3156570849 hasConcept C159110408 @default.
• W3156570849 hasConcept C179755657 @default.
• W3156570849 hasConcept C1862650 @default.
• W3156570849 hasConcept C194828623 @default.
• W3156570849 hasConcept C2779951463 @default.
• W3156570849 hasConcept C2780645631 @default.
• W3156570849 hasConcept C2908647359 @default.
• W3156570849 hasConcept C3019080777 @default.
• W3156570849 hasConcept C500558357 @default.
• W3156570849 hasConcept C64332521 @default.
• W3156570849 hasConcept C71924100 @default.
• W3156570849 hasConcept C78519656 @default.
• W3156570849 hasConcept C99454951 @default.
• W3156570849 hasConceptScore W3156570849C112930515 @default.
• W3156570849 hasConceptScore W3156570849C126322002 @default.
• W3156570849 hasConceptScore W3156570849C127413603 @default.
• W3156570849 hasConceptScore W3156570849C133925201 @default.
• W3156570849 hasConceptScore W3156570849C159110408 @default.
• W3156570849 hasConceptScore W3156570849C179755657 @default.
• W3156570849 hasConceptScore W3156570849C1862650 @default.
• W3156570849 hasConceptScore W3156570849C194828623 @default.
• W3156570849 hasConceptScore W3156570849C2779951463 @default.
• W3156570849 hasConceptScore W3156570849C2780645631 @default.
• W3156570849 hasConceptScore W3156570849C2908647359 @default.
• W3156570849 hasConceptScore W3156570849C3019080777 @default.
• W3156570849 hasConceptScore W3156570849C500558357 @default.
• W3156570849 hasConceptScore W3156570849C64332521 @default.
• W3156570849 hasConceptScore W3156570849C71924100 @default.
• W3156570849 hasConceptScore W3156570849C78519656 @default.
• W3156570849 hasConceptScore W3156570849C99454951 @default.
• W3156570849 hasIssue "6" @default.
• W3156570849 hasLocation W31565708491 @default.
• W3156570849 hasOpenAccess W3156570849 @default.
• W3156570849 hasPrimaryLocation W31565708491 @default.
• W3156570849 hasRelatedWork W2067182892 @default.
• W3156570849 hasRelatedWork W2213541780 @default.
• W3156570849 hasRelatedWork W2310170993 @default.
• W3156570849 hasRelatedWork W2934583907 @default.
• W3156570849 hasRelatedWork W3017217963 @default.
• W3156570849 hasRelatedWork W3125858761 @default.
• W3156570849 hasRelatedWork W3137921130 @default.
• W3156570849 hasRelatedWork W3139605315 @default.
• W3156570849 hasRelatedWork W4225283355 @default.
• W3156570849 hasRelatedWork W4300753267 @default.
• W3156570849 hasVolume "61" @default.
• W3156570849 isParatext "false" @default.
• W3156570849 isRetracted "false" @default.

• next